Basic Information
| LncRNA/CircRNA Name | LINCRNA-p21 |
| Synonyms | TP53COR1, TRP53COR1, linc-p21, lincRNA-p21 |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | rapamycin,3-bromopyruvate (3-Brpa) | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | prostate cancer |
| ICD-0-3 | C61.9 |
| Methods | qPCR, Western blot |
| Sample | cell lines (DU145 and LNCaP) |
| Expression Pattern | down-regulated |
| Function Description | lincRNA-p21 silencing in DU145 and LNCaP cells induced up-regulation of PKM2 and activation of glycolysis, which could be reversed by PKM2 knockdown or rapamycin treatment.the proliferation and tumorigenesis of lincRNA-p21-silenced prostate cancer cells were significantly inhibited after knocking down PKM2. 3-bromopyruvate (3-Brpa) or rapamycin treatment largely decreased the tumour burden. PKM2 expression was inversely correlated with the lincRNA-p21 level and the survival of prostate cancer patients. |
| Pubmed ID | 28994148 |
| Year | 2017 |
| Title | LincRNA-p21 suppresses development of human prostate cancer through inhibition of PKM2. |
External Links
| Links for LINCRNA-p21 | GenBank HGNC NONCODE |
| Links for prostate cancer | OMIM COSMIC |